GOTHENBURG, Sweden, April 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Wednesday, May 21, 2025. The information in the press release is intended for investors. The shareholders in Isofol Medical AB (publ), […]
GOTHENBURG, Sweden, February 19, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report for January – December 2024 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. CEO’s comment ” At the end of 2024, we received positive feedback
Isofol Medical AB (publ) publishes year-end report, January – December 2024 Read More »
GOTHENBURG, Sweden, November 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the members of the nomination committee for the Annual General Meeting 2025 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting 2024. The information
Isofol appoints nomination committee ahead of the Annual General Meeting 2025 Read More »
GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Third quarter, July–September 2024 Net revenue amounted to kSEK 0 (0) and
Isofol Medical AB (publ) publishes interim report, January–September 2024 Read More »
GOTHENBURG, Sweden, September 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the company has terminated the liquidity guarantee agreement with Pareto Securities. The agreement expires on September 13, 2024. The information in the press release is intended for investors. The purpose of a liquidity guarantee agreement is to improve share
Isofol terminates liquidity guarantee agreement Read More »
GOTHENBURG, Sweden, July 30, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive financial experience from biotech and pharmaceutical companies and will assume the position on August 13. The information in the press release is intended for
Isofol appoints Margareta Hagman as new Chief Financial Officer Read More »
GOTHENBURG, Sweden, June 12, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that Magnus Hurst, Chief Financial Officer, is leaving the company at the beginning of September for family reasons. The information in the press release is intended for investors. Magnus Hurst has held the position as CFO on a part-time consultancy
Isofol’s Chief Financial Officer to leave the company Read More »
Today on May 8, 2024 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting (“AGM”) at which the following principal resolutions were passed by the shareholders. The information in the press release is intended for investors. Adoption of income statements and balance sheets for 2024 and discharge from liability
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024 Read More »
GOTHENBURG, Sweden, May 8, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. First quarter, January–March 2024 Net revenue amounted to kSEK 0 (721) and
Isofol Medical AB (publ) publishes interim report, January–March 2024 Read More »
GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Wednesday, May 8, 2024. The information in the press release is intended for investors. The shareholders in Isofol Medical AB (publ),
